Search clinical trials for: Autologous anti-CD19 CAR-T cell injection

Total 2142 results

Allife Medical Science and Technology Co., Ltd.

Unknown

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Refractory B-Cell Lymphoma
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

China
Joshua Sasine, MD, PhD

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Multiple Myeloma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Large B-cell Lymphoma

United States
Wuhan Union Hospital, China

Not yet recruiting

CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Dipenkumar Modi
Genmab

Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Relapsed Cancer | Refractory Cancer | Large Cell Lymphoma, Diffuse

United States
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

B-cell Non Hodgkin Lymphoma

China
920th Hospital of Joint Logistics Support Force...

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Acute Myeloid Leukemia

China
Guangdong Second Provincial General Hospital

Not yet recruiting

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases (BAH247)

Autoimmune Diseases | Systemic Lupus Erythematosus | Sjogren's Syndrome | Systemic Lupus Erythematosus Acute

China
Sorrento Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma

United States
Verismo Therapeutics

Recruiting

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Ovarian Cancer | Mesothelioma, Malignant | Cholangiocarcinoma Recurrent

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Institute of Hematology & Blood Diseases Hospital...
Suzhou Fundamenta Therapeutics

Recruiting

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Autoimmune Hemolytic Anemia | CD19 CAR-T Cell Infusion

China
Xijing Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Shanghai Longyao Biotechnology Inc., Ltd.
Xuzhou Medical University; Shanghai Jiao Tong University School of Medicine

Unknown

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

Recurrent or Refractory B Cell Malignancy

China
Allife Medical Science and Technology Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Refractory B-Cell Lymphoma
Bioray Laboratories
First Affiliated Hospital of Zhejiang University

Completed

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

B-cell Lymphoma

China
Juno Therapeutics, a Subsidiary of Celgene

Terminated

Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET)

Acute Lymphoblastic Leukemia

United States
Wenbin Qian
Zhejiang Provincial Tongde Hospital

Unknown

Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

B Cell Lymphoma

China
Changhai Hospital

Recruiting

A Study of IMC008 for Advanced Solid Tumors

Advanced Solid Tumor

China
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Multiple Myeloma

United States, Canada
Zhejiang University
Shanghai First Song Therapeutics Co., Ltd

Not yet recruiting

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
University of Pennsylvania

Not yet recruiting

Retreatment With CTL019/CTL119

Lymphoma, B-Cell

United States
Nanjing Legend Biotech Co.
Ruijin Hospital; Second Affiliated Hospital of Xi'an Jiaotong University; Shanghai... and other collaborators

Active, not recruiting

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)

Refractory or Relapsed Multiple Myeloma
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Acute Myeloid Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma

United States
Eden BioCell Ltd.
National Taiwan University Hospital

Terminated

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

Taiwan
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

B-cell Lymphoma

China
Beijing Tsinghua Chang Gung Hospital
China Immunotech Pharmaceuticals Co.Ltd.

Suspended

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

B-cell Non-Hodgkin's Lymphoma

China
Autolus Limited

Completed

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)

Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic Leukemia

United Kingdom
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Refractory | B-Cell Lymphoma Stage I | Relapsed

China
University of Sao Paulo

Completed

Intravitreal Bone Marrow-Derived Stem Cells in Patients With Macular Degeneration (AMDCELL)

Age Related Macular Degeneration and Stargartd

Brazil
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

B-cell Leukemia

China
Hadassah Medical Organization

Completed

T Cell Vaccination in Patients With Progressive Multiple Sclerosis

Multiple Sclerosis

Israel
Second Affiliated Hospital, School of Medicine,...

Completed

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

Transformed Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Unknown

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia

China
Chinese PLA General Hospital

Recruiting

Chidamide Bridging for CAR-T Therapy

Non Hodgkin's Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects With R/R MM

Multiple Myeloma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; 920th Hospital of Joint Logistics Support... and other collaborators

Not yet recruiting

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin Lymphoma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Soochow University

Recruiting

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
OneChain Immunotherapeutics
Hospital Clinic of Barcelona; Hospital Sant Joan de Deu; BioClever 2005 S.L.

Recruiting

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (CARxALL)

T-cell Acute Lymphoblastic Leukemia | Lymphoblastic T-Cell Lymphoma

Spain
Chinese PLA General Hospital

Recruiting

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
RenJi Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

CD19-redirected Autologous Cells (CAR-CD19 T Cells)

CD19 Positive Malignant B-cell Leukemia and Lymphoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China

Search clinical trials for: Autologous anti-CD19 CAR-T cell injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations